Today Only – Celebrate Leap Day with a 60% discount on Datamonitor Reports!

For more information on Datamonitor strategy reports, please email BioMedTracker or call BioMedTracker Client Services at (858) 200-2357.
Datamonitor's independent research and analysis provides extensive coverage of major disease areas, companies and strategic issues, giving you the perspective to identify opportunities and threats arising from shifting market dynamics and the insights to respond with faster, more effective decision-making. This strategy report focuses on Big Pharma Licensing Trends with company analyses, case studies, therapy area analysis, and deal economics.
Highlights

• Deal volume increased but Big Pharma's overall share was small.
• Big Pharma represented the majority of deal-making spend.
• 2014 and 2015 were stand-out years in Big Pharma deal-making.
• AstraZeneca was the leading dealmaker by overall volume within the Big Pharma peer set (AZN).
• Johnson & Johnson signed key cancer deals and formed an innovation initiative (JNJ).
• Roche continued oncology momentum but deal-making showed importance of other therapeutic areas (Roche).
• Pfizer's in-licensing fluctuated while out-licensing efforts increased (PFE).
• Overall, out-licensing increased by 42% and Amgen and Eli Lilly evenly split in- and outlicensing (LLY).

For our disclosures, please read the BioMedTracker Research Standards.